Ads
related to: acute myeloid leukemia treatment- Dosing & Monitoring
Twice Daily
Oral Dosing.
- Mechanism of Action
Inhibits Mutant IDHI and
Restores Myeloblast Differentiation
- Access & Resources
Support is Available for
You and Your Patients.
- Safety
Learn More About Well Characterized
Safety Profile.
- Dosing & Monitoring
Search results
Curis reports progress in leukemia study with expanded patient dataset By Investing.com
Investing.com· 6 days agoCuris, Inc. (NASDAQ: CRIS), a biotechnology company, has announced an expansion of its dataset in an...
Earnings call: Aptose Biosciences targets AML treatment with tuspetinib By Investing.com
Investing.com· 6 days agoAptose Biosciences (NASDAQ:APTO) has focused its efforts on developing tuspetinib as part of a novel...
Benzene Exposure Linked to Acute Myeloid Leukemia, Aplastic Anemia, and Lymphomas | JD Supra
JD Supra· 4 days agoIf you have been diagnosed with acute myeloid leukemia but cannot figure out why, benzene may be responsible. Benzene, a chemical used ...
Ryvu Therapeutics First Quarter 2024 Financial Results and Corporate Update
FOX 59 Indianapolis· 6 days agoAs of May 9, 2024, Ryvu's cash position was $59.0M, inclusive of the first tranche of €8M in venture...
Patients Over 80 Still Benefit From Treatment for AML Blood Cancer
Alaska Superstation· 7 days agoSeniors over 80 with acute myeloid leukemia can safely and effectively take the standard targeted...
Actinium Announces Oral Presentation Detailing Improved Survival Outcomes in TP53 Positive Patients...
WKBN 27 Youngstown· 6 days agoThe Phase 3 SIERRA trial enrolled 153 patients ages 55 and above with active relapsed or refractory acute myeloid leukemia (r/r AML) ...
Local Leukemia & Lymphoma Society holds annual fundraiser for blood cancer research
Local 12 Cincinnati· 4 days agoThe local chapter of the Leukemia and Lymphoma Society held its annual fundraiser to raise money for...
Bio-Path Holdings Inc (BPTH) Q1 2024 Earnings Call Transcript Highlights: Strategic Advances ...
GuruFocus.com via Yahoo Finance· 5 days agoQ & A Highlights Q: Can you provide an update on the progress of your lead product candidate, prexigebersen, for the treatment of acute myeloid ...
Anti-diabetic treatment associated with reduced risk of developing blood cancer
Medical Xpress· 4 days ago"Our team was interested in understanding what other effects we see with commonly prescribed ...
Ryvu Therapeutics to present clinical and preclinical data on RVU120 at the 2024 European Hematology...
FOX 23 News Albany· 7 days agoUpdated data from the Phase I trial of RVU120 in patients with relapsed/refractory acute myeloid ...